TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14730405

Group type: EXPERIMENTAL
Intervention: C(15)O(2) or H(2)(15)O, (15)O‐labelled carbon monoxide (C(15)O) and (15)O‐labelled oxygen ((15)O(2))
Number of subjects: 70
Study: 11391739

Group type: EXPERIMENTAL
Intervention: N‐0923 TDS 33.5 mg
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: N‐0923 TDS 67 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9164591

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg in SOC
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: d-amphetamine (10 or 20 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 8485430

Group type: EXPERIMENTAL
Intervention: Low alcohol (0.025% BAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate alcohol (0.05% BAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 0
Study: 3618993

Group type: EXPERIMENTAL
Intervention: Experimental group (received prerecorded audio tape with suggestions)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (did not receive the audio tape)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pre-operative medication
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Postoperative anxiety
Number of subjects: 30
Study: 29675546

Group type: EXPERIMENTAL
Intervention: Recommendations and telehealth intervention (Group R)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 60
Study: 27567468

Group type: EXPERIMENTAL
Intervention: Feedback program for faculty members failing to correctly report CFs
Number of subjects: 2100
Study: 25037645

Group type: EXPERIMENTAL
Intervention: Shopping vouchers for validated smoking cessation in pregnancy
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Shopping vouchers for smoking cessation after birth
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Shopping vouchers for a smoke-free home
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Shopping vouchers for proven breastfeeding
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Free breast pump
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Payments to health services for reaching smoking cessation in pregnancy targets
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Payments to health services for reaching breastfeeding targets
Number of subjects: 1144

Group type: EXPERIMENTAL
Intervention: Up to £40/month vouchers for behaviour change
Number of subjects: 1144
Study: 22711239

Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation on the right
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Cervical thrust manipulation on the left
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Thoracic thrust manipulation
Number of subjects: 90
Study: 20210697

Group type: EXPERIMENTAL
Intervention: Stoller afferent neuro-stimulation (SANS) with 4 mgs of tolterodine orally for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anti-muscarinic treatment alone (4 mgs of tolterodine orally for 12 weeks)
Number of subjects: 40
Study: 17620783

Group type: EXPERIMENTAL
Intervention: Intravenous fluid therapy
Number of subjects: 133

Group type: COMPARATOR
Intervention: Oral fluid therapy
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Normonatremic runners
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Hypernatremic runners
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Hyponatremic runners
Number of subjects: 133
Study: 15815811

Group type: EXPERIMENTAL
Intervention: Preservative-containing saline solution during BTX-A injections in the upper face (n = 60)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Preservative-containing saline solution during BTX-A injections in the neck (n = 15)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Preservative-containing saline solution during BTX-A injections in the axillary region (n = 18)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no preservative-containing saline solution) in the upper face (n = 60)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no preservative-containing saline solution) in the neck (n = 15)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control group (no preservative-containing saline solution) in the axillary region (n = 18)
Number of subjects: 93
Study: 12208448

Group type: EXPERIMENTAL
Intervention: Computer simulation study
Number of subjects: 0

Group type: COMPARATOR
Intervention: Textbook study
Number of subjects: 0
Study: 10425979

Group type: EXPERIMENTAL
Intervention: 200 mg of trazodone
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 7741366

Group type: EXPERIMENTAL
Intervention: Comprehensive pulmonary rehabilitation
Number of subjects: 119

Group type: COMPARATOR
Intervention: Education alone
Number of subjects: 119
Study: 2192369

Group type: EXPERIMENTAL
Intervention: Tulobuterol 2.0 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Fenoterol 2.5 mg
Number of subjects: 26
Study: 7042370

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once a day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once a day
Number of subjects: 45
Study: 31714424

Group type: EXPERIMENTAL
Intervention: HIV-infected patients on ART
Number of subjects: 29
Study: 30153978

Group type: EXPERIMENTAL
Intervention: Ixabepilone plus capecitabine
Number of subjects: 443

Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 443
Study: 27426212

Group type: EXPERIMENTAL
Intervention: Calmer Life intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Enhanced Community Care
Number of subjects: 40
Study: 24177001

Group type: EXPERIMENTAL
Intervention: Higher serum lysyl oxidase-like 2 (sLOXL2) levels (>800 pg·mL(‐1)) in ARTEMIS-IPF cohort
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Higher serum lysyl oxidase-like 2 (sLOXL2) levels (>700 pg·mL(‐1)) in GAP cohort with baseline spirometric data (n=70)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Higher serum lysyl oxidase-like 2 (sLOXL2) levels among all GAP subjects
Number of subjects: 173
Study: 22112421

Group type: EXPERIMENTAL
Intervention: Training aimed at improving psychological flexibility
Number of subjects: 81

Group type: COMPARATOR
Intervention: Training in practical knowledge and skills related to pain management
Number of subjects: 81
Study: 19918965

Group type: EXPERIMENTAL
Intervention: Intravaginal progesterone gel, 90 mg daily
Number of subjects: 547

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study: 17846090

Group type: EXPERIMENTAL
Intervention: Sitting physician posture
Number of subjects: 173

Group type: COMPARATOR
Intervention: Standing physician posture
Number of subjects: 173
Study: 15090373

Group type: EXPERIMENTAL
Intervention: Arthroscopic capsulolabroplasty
Number of subjects: 31
Study: 11898538

Group type: EXPERIMENTAL
Intervention: Dopamine agonists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levodopa
Number of subjects: 0
Study: 9655769

Group type: EXPERIMENTAL
Intervention: 6 mg/kg caffeine
Number of subjects: 10

Group type: COMPARATOR
Intervention: 6 mg/kg fructose (placebo)
Number of subjects: 10
Study: 7658819

Group type: EXPERIMENTAL
Intervention: Cefuroxime (4.5 g/day intravenously) from admission
Number of subjects: 60

Group type: COMPARATOR
Intervention: No antibiotic treatment until clinical or microbiologically verified infection
Number of subjects: 60
Study: 2787297

Group type: EXPERIMENTAL
Intervention: Midazolam (0.2 mg/kg i.v.)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Diazepam (0.4 mg/kg i.v.)
Number of subjects: 75
Study: 820228

Group type: EXPERIMENTAL
Intervention: Low-dose intramuscular insulin therapy
Number of subjects: 48

Group type: COMPARATOR
Intervention: High-dose insulin therapy (intravenous and subcutaneous)
Number of subjects: 48
Study: 30611407

Group type: EXPERIMENTAL
Intervention: Oil-based contrast
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water-based contrast
Number of subjects: 0
Study: 28007428

Group type: EXPERIMENTAL
Intervention: Topical 10% azithromycin applied twice daily for 3 consecutive days
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 3 consecutive days
Number of subjects: 1371

Group type: EXPERIMENTAL
Intervention: Topical 10% azithromycin
Number of subjects: 1371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1371
Study: 26026141

Group type: EXPERIMENTAL
Intervention: Humor group (viewed humorous videos)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetic group (viewed humorous videos)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (did not watch humor video)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Humor group
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diabetic group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 23485934

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21701268

Group type: EXPERIMENTAL
Intervention: Hypertonic saline solution (HSS) with furosemide (250 mg) and moderate Na restriction (120 mmol)
Number of subjects: 1771

Group type: COMPARATOR
Intervention: Furosemide (250 mg) without HSS and low Na diet (80 mmol)
Number of subjects: 1771
Study: 19798725

Group type: EXPERIMENTAL
Intervention: rAAV1.tMCK.hSGCA gene therapy
Number of subjects: 3

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 3
Study: 17102650

Group type: EXPERIMENTAL
Intervention: 1 g tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 0
Study: 15526307

Group type: EXPERIMENTAL
Intervention: Venlafaxine ER 75-150 mg/day
Number of subjects: 151

Group type: COMPARATOR
Intervention: Citalopram 10-20 mg/day
Number of subjects: 151
Study: 11585712

Group type: COMPARATOR
Intervention: Randomised withdrawal studies in responders/remitters
Number of subjects: 14

Group type: COMPARATOR
Intervention: Extension studies in responders without re-randomisation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Proposed novel design
Number of subjects: 14
Study: 9391919

Group type: EXPERIMENTAL
Intervention: Alcohol (0.62 g/kg for men, 0.54 g/kg for women)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 48
Study: 7560695

Group type: EXPERIMENTAL
Intervention: Progressive resistance strength training (12 weeks, 3 sessions per week: 1 supervised, 2 unsupervised)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 1972837

Group type: EXPERIMENTAL
Intervention: Mezinc (zinc oxide medicated dressing)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Duoderm (hydrocolloid dressing)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Mezinc
Number of subjects: 43

Group type: COMPARATOR
Intervention: Duoderm
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both dressings
Number of subjects: 43
Study: 7349932

Group type: EXPERIMENTAL
Intervention: Individual advice twice a year and health education campaign in intervention factories
Number of subjects: 19390

Group type: COMPARATOR
Intervention: Baseline examination for 10% of randomly chosen subjects
Number of subjects: 19390

Group type: EXPERIMENTAL
Intervention: Random samples from intervention group
Number of subjects: 19390

Group type: COMPARATOR
Intervention: Random samples from control group
Number of subjects: 19390
Study: 31821220

Group type: EXPERIMENTAL
Intervention: High-dose group (HDG): three 90-minute yoga classes and four 30-minute homework sessions per week for 12 weeks.
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Low-dose group (LDG): two 90-minute yoga classes and three 30-minute homework sessions per week for 12 weeks.
Number of subjects: 32
Study: 28946736

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) 0.5 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lamivudine (LAM) 100 mg/day
Number of subjects: 120
Study: 25897158

Group type: EXPERIMENTAL
Intervention: Nivolumab 3 mg/kg intravenously once every 2 weeks for up to 96 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Nivolumab 1, 3, or 10 mg/kg intravenously once every 2 weeks for up to 96 weeks
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 129
Study: 24135303

Group type: EXPERIMENTAL
Intervention: Renal stenting
Number of subjects: 37
Study: 21873705

Group type: EXPERIMENTAL
Intervention: Colchicine (1.0 to 2.0 mg on the first day followed by 0.5 to 1.0 mg/d for 6 months)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Colchicine and Placebo
Number of subjects: 120
Study: 19688320

Group type: EXPERIMENTAL
Intervention: Yinzhihuang Oral Liquid (YOL), 5 mL each time, twice daily
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 242
Study: 17944632

Group type: EXPERIMENTAL
Intervention: Hyperoxia (oxygen fraction > 0.96)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (oxygen fraction 0.4)
Number of subjects: 40
Study: 15474732

Group type: EXPERIMENTAL
Intervention: Transgenic corn expressing 1 mg of LT-B, fed in three doses of 2.1 g each.
Number of subjects: 9
Study: 11528274

Group type: EXPERIMENTAL
Intervention: Volatile oil administered by gargling for 14 consecutive nights
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo administered for 14 consecutive nights
Number of subjects: 72
Study: 8805169

Group type: EXPERIMENTAL
Intervention: Gentamicin sulfate (5 mg/kg daily) for > 10 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Gentamicin sulfate (5 mg/kg daily) for <= 7 days
Number of subjects: 200
Study: 1370915

Group type: EXPERIMENTAL
Intervention: MOPP and RT
Number of subjects: 120

Group type: COMPARATOR
Intervention: TBV and RT
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: MOPP and RT for clinical Stage IIIA
Number of subjects: 120

Group type: COMPARATOR
Intervention: TBV and RT for clinical Stage IIIA
Number of subjects: 120
Study: 6236095

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (Ip) 40 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenoterol (Fen) 400 micrograms
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combination of Ipratropium bromide and Fenoterol (Ip/Fen)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31888594

Group type: EXPERIMENTAL
Intervention: Unmet need for family planning
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Never use of family planning before survey
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Multiparity
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Perceived husband's attitude as disapproval
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Lack of counseling from health workers
Number of subjects: 348

Group type: EXPERIMENTAL
Intervention: Unavailability of Radio and/or Television in the house
Number of subjects: 348
Study: 28433267

Group type: COMPARATOR
Intervention: 20 μg vitamin D3
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 10 μg calcifediol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 15 μg calcifediol
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Calcifediol (10 and 15 μg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Calcifediol and vitamin D3
Number of subjects: 59
Study: 27507582

Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAP)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intravenous lignocaine
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: All groups (TAP, intravenous lignocaine, placebo)
Number of subjects: 101
Study: 25618125

Group type: EXPERIMENTAL
Intervention: High-frequency ultrasound (HFU) therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: MIST ultrasound therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ultrasound therapy (HFU and MIST combined)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups (HFU, MIST, and Standard treatment)
Number of subjects: 90
Study: 21262931

Group type: EXPERIMENTAL
Intervention: 20 per cent carbamide peroxide (CP) at-home bleaching agent, bonded 24 hours after bleaching (n = 40)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20 per cent carbamide peroxide (CP) at-home bleaching agent, bonded 14 days after bleaching (n = 40)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no bleaching, n = 40)
Number of subjects: 120
Study: 19341192

Group type: EXPERIMENTAL
Intervention: Extended lymphadenectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Operative mortality less than 2%
Number of subjects: 0
Study: 17686443

Group type: EXPERIMENTAL
Intervention: Enzastaurin (novel targeted therapy, monotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine and pemetrexed (new drugs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacogenomics (tailored therapy)
Number of subjects: 0
Study: 16335170

Group type: EXPERIMENTAL
Intervention: Early loading group (20 implants); mean change in ISQ: -0.08 +/- 0.77; mean bone loss: 0.69 +/- 0.15 mm.
Number of subjects: 22

Group type: COMPARATOR
Intervention: Unloaded group (21 implants); mean change in ISQ: 1.33 +/- 1.65; mean bone loss: 0.53 +/- 0.18 mm.
Number of subjects: 22
Study: 12220337

Group type: EXPERIMENTAL
Intervention: Compoglass F
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Dyract AP
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: F2000
Number of subjects: 175
Study: 10211155

Group type: EXPERIMENTAL
Intervention: Intensive case management (case load per worker ≤ 15 patients)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard case management (case load 30-35 patients)
Number of subjects: 700
Study: 7558234

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 12
Study: 2160358

Group type: EXPERIMENTAL
Intervention: Long-acting propranolol 60 mg once a day for 12 weeks
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once a day for 12 weeks
Number of subjects: 39
Study: 6113920

Group type: EXPERIMENTAL
Intervention: Tiotidine 25 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiotidine 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiotidine 100 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tiotidine 150 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cimetidine 300 mg
Number of subjects: 12
Study: 30636448

Group type: EXPERIMENTAL
Intervention: VAMOS strategy (Health‐Improving Active Life) for 12 weeks
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 291
Study: 29145873

Group type: COMPARATOR
Intervention: Individual pelvic floor muscle training (PFMT)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Group pelvic floor muscle training (PFMT)
Number of subjects: 364
Study: 25657053

Group type: EXPERIMENTAL
Intervention: Physical Activity Self-Management Intervention (PASM), n = 149
Number of subjects: 325

Group type: COMPARATOR
Intervention: Usual Care (UC), n = 156
Number of subjects: 325
Study: 24704942

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and endobronchial photodynamic therapy (PDT) with photosensitizer agent chlorine E6 and 662nm laser light before each of the three courses of chemotherapy.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Chemotherapy alone (No-PDT arm).
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and endobronchial PDT (PDT arm).
Number of subjects: 42
Study: 22791944

Group type: EXPERIMENTAL
Intervention: Epidural combined general anesthesia (G + E)
Number of subjects: 61

Group type: COMPARATOR
Intervention: General anesthesia (G)
Number of subjects: 61
Study: 18955144

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17214829

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 15385354

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the first tactile TOF response (Group I) during sevoflurane anesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the second tactile TOF response (Group II) during sevoflurane anesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the third tactile TOF response (Group III) during sevoflurane anesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.07 mg/kg administered on reappearance of the fourth tactile TOF response (Group IV) during sevoflurane anesthesia
Number of subjects: 160
Study: 11477585

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.10 mg/kg bodyweight, irradiated 48 hours after drug application at a light dose of 5 J/cm².
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using meta-tetra(hydroxyphenyl)chlorin (m-THPC) at a dose of 0.15 mg/kg bodyweight, illuminated 96 hours after photosensitization at a light dose of 10 J/cm².
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) using m-THPC.
Number of subjects: 7
Study: 9748876

Group type: EXPERIMENTAL
Intervention: Interferon alpha-2b
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sequential maintenance therapy (interferon alpha-2b for 3 months followed by dexamethasone)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with melphalan (200 mg/m2)
Number of subjects: 55